INmune Bio Signs Uniphar Deal to Build Global Access Route…
By Karthik Subramanian
Source excerpt · FinanceFeeds
Key Facts INmune Bio (NASDAQ: INMB) has signed a Master Services Agreement with Uniphar Durbin Ireland Limited covering international access, distribution and commercialisation of Ebstrocel™. Ebstrocel™ is an investigational allogeneic stromal cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) and has not been approved by any regulator. The first use of the framework is named-patie…